drugset / Trial / NCT01103622
Investigate the Effect of AZD1656 on the Pharmacokinetics of Digoxin in Type 2 Diabetes Mellitus Patients
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of this study is to determine whether AZD1656 will affect the pharmacokinetics (PK) of digoxin in type 2 diabetes mellitus (T2DM) patients.
Timeline
- Start
- 2010-06
- Primary completion
- 2010-12
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD1656 | Small molecule | — | Oral |
| Subject | Digoxin | Other / unclassified | — | Oral |